AD

Andrea Deutsch

Head Of Global PV Operations & Deputy QPPV at Valneva

Andrea Deutsch's work experience begins in 2001 as a CTA at the Medical University of Vienna. Andrea then worked as a CTA at the Veterinary University Vienna from 2005 to 2006. From 2009 to 2012, they were a University Assistant at the University of Vienna. In 2013, they held various roles, including being an Assistant to the Quality Manager at public Pharmacy and a University Lecturer at the University of Vienna. Andrea also worked as an Instructor at MERA Bildungsholding GmbH. In 2013, they joined Sanova Pharma GesmbH as a Pharmacovigilance Manager/Deputy QPPV. From 2014 to 2016, they served as the Corporate Drug Safety Officer at Octapharma. In 2016, they became the Manager of Pharmacovigilance at PharmaLex GmbH. Since 2017, they have been working at Valneva, initially as a Medical Information and Pharmacovigilance Expert, Deputy QPPV, followed by roles as Senior Pharmacovigilance Expert & Deputy QPPV, Manager PV Operations & Deputy QPPV, and currently as the Head of Global PV Operations & Deputy QPPV.

Andrea Deutsch holds a Master's degree in Pharmazieverwaltung und Pharmazierichtlinien und regulatorische Angelegenheiten, which they obtained from IMC Krems University of Applied Sciences between 2011 and 2013. Prior to that, they completed a Diplomstudium in Biochemie und Molekularbiologie at the University of Vienna from 2001 to 2008. Their education also includes a Diplom in Chemie from HTBLVA Rosensteingasse, which they earned from 1998 to 2000. Additionally, Andrea has achieved certifications such as certified Quality Manager & internal Quality Auditor from TÜV AUSTRIA in 2022 and Foundational ICH-Good Clinical Practice (GCP) E6 (R2) Training from ECCRT in 2020.

Location

Vienna, Austria

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Valneva

2 followers

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.


Industries

Employees

501-1,000

Links